NST-SpARk
Phase 1- Indications
- Negative symptoms of schizophrenia
Company intelligence / Profile preview
North Shore Therapeutics
Lewes, Delaware, United Statesnorthshore.health ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 1
01
Overview
North Shore Therapeutics has completed a Phase 1B feasibility study of its augmented reality application "NST-SPARK" targeting negative symptoms in schizophrenia. The study showed high engagement, positive attitude shifts, and concrete progress toward life goals among participants. A controlled trial to assess efficacy is planned as the next step.
- Therapeutic areas
- Psychiatry
- Modalities
- Digital therapeuticAugmented reality-based therapySoftware as a medical device (SaMD)
- Industry
- Digital Health Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on North Shore Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on North Shore Therapeutics.